Patient preference, efficacy, and compliance with zoledronic acid for glucocorticoid-induced osteoporosis in patients with autoimmune diseases
Postgraduate Medical Journal · 2024
DOI: 10.1093/postmj/qgae003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Postgraduate Medical Journal, 2024. Verfasst von Ji-Won Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Ajou University School of Medicine, Suwon 16499, Republic of Korea. Hauptthemen laut MEDLINE: Zoledronic Acid, Osteoporosis, Glucocorticoids, Bone Density Conservation Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Korea Health Technology R&D Project, Korea Health Industry Development Institute, Ministry of Health and Welfare.
Abstract (Originalsprache)
Purpose
We evaluated the preference, patient satisfaction, and efficacy of zoledronic acid compared with oral bisphosphonates (BPs) for glucocorticoid-induced osteoporosis (GIOP) in patients with autoimmune diseases.
Methods
We enrolled 50 patients with new fractures or osteoporosis detected on follow-up bone densitometry after at least 1 year of oral BP use among patients diagnosed with GIOP during treatment for autoimmune diseases. After 1 year of zoledronic acid treatment, patients completed a survey for preference and satisfaction assessment. Treatment efficacy was analysed by comparing bone mineral density changes and fractures with those in a control group of patients who continued oral BP use.
Results
Age, sex, treatment duration, and medication history did not differ significantly between the two groups. Among the participants, 86.7% preferred and were more satisfied with intravenous zoledronic acid than with oral BPs, primarily because of the convenience of its administration interval. Only two patients (4%) reported infusion-related adverse events with zoledronic acid. Furthermore, no significant differences were observed in the annualized percentage change in the bone mineral density of the lumbar spine, femur neck, and hip between patients receiving zoledronic acid and those receiving oral BPs. The occurrence of new fractures was consistent across both groups, with two cases in each, showing no significant differences.
Conclusion
Patients showed a preference for and greater satisfaction with zoledronic acid, and its efficacy in treating osteoporosis was comparable to that of oral BPs. Therefore, zoledronic acid is a suitable treatment option for GIOP in patients with autoimmune diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Ajou University School of Medicine, Suwon 16499, Republic of Korea.
- Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea.
ORCID-Profile: Chang-Hee Suh
Förderung
- Korea Health Technology R&D Project
- Korea Health Industry Development Institute
- Ministry of Health and Welfare
Zitieren
APA
Kim, J. W., Jung, J. Y., Kim, H. A., Son, H., & Suh, C. H. (2024). Patient preference, efficacy, and compliance with zoledronic acid for glucocorticoid-induced osteoporosis in patients with autoimmune diseases. Postgraduate Medical Journal. https://doi.org/10.1093/postmj/qgae003
Vancouver
Kim JW, Jung JY, Kim HA, Son H, Suh CH. Patient preference, efficacy, and compliance with zoledronic acid for glucocorticoid-induced osteoporosis in patients with autoimmune diseases. Postgraduate Medical Journal. 2024. doi:10.1093/postmj/qgae003
BibTeX
@article{Kim2024,
author = {Kim, Ji-Won and Jung, Ju-Yang and Kim, Hyoun-Ah and Son, Heejun and Suh, Chang-Hee},
title = {Patient preference, efficacy, and compliance with zoledronic acid for glucocorticoid-induced osteoporosis in patients with autoimmune diseases},
journal = {Postgraduate Medical Journal},
year = {2024},
doi = {10.1093/postmj/qgae003}
}
EUVIMED